deltatrials
Terminated PHASE1 INTERVENTIONAL 2-arm NCT04088188

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

A Phase I, Multi-Center, Open Label, Dose De-Escalation and Expansion Study of Gemcitabine and Cisplatin With AG120 or Pemigatinib for Advanced Cholangiocarcinoma

Sponsor: Academic and Community Cancer Research United

Conditions Advanced Cholangiocarcinoma Metastatic Cholangiocarcinoma Unresectable Cholangiocarcinoma
Interventions Cisplatin Gemcitabine Ivosidenib Pemigatinib
Updated 19 times since 2019 Last updated: May 3, 2024 Started: Jan 25, 2021 Primary completion: Dec 1, 2023 Completion: Dec 1, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low accrual

Other terminated trials from Academic and Community Cancer Research United

See all terminations from Academic and Community Cancer Research United

Other Advanced Cholangiocarcinoma trials with similar outcome

Browse all Advanced Cholangiocarcinoma trials

A PHASE1 clinical study on Advanced Cholangiocarcinoma and Metastatic Cholangiocarcinoma, this trial is terminated or withdrawn. The trial is conducted by Academic and Community Cancer Research United and has accumulated 19 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshot~Mar 2020 – ~Aug 2020 · 5 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Feb 2022 · 10 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Mar 2023 · 8 months · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Jun 2024 · 10 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jun 2024 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  4. Aug 2023 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Jul 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE1

▶ Show 14 earlier versions

  1. Jun 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Mar 2023 — Jun 2023 [monthly]

    Recruiting PHASE1

  3. Jul 2022 — Mar 2023 [monthly]

    Recruiting PHASE1

  4. May 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  5. Mar 2022 — May 2022 [monthly]

    Recruiting PHASE1

  6. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE1

  7. Apr 2021 — Feb 2022 [monthly]

    Recruiting PHASE1

  8. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  9. Jan 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE1

  10. Nov 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE1

  11. Aug 2020 — Nov 2020 [monthly]

    Not Yet Recruiting PHASE1

  12. Mar 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE1

  13. Nov 2019 — Mar 2020 [monthly]

    Not Yet Recruiting PHASE1

  14. Oct 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Academic and Community Cancer Research United
  • National Cancer Institute (NCI)
Data source: Academic and Community Cancer Research United

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations